Clinical Trial Update: Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine combined with epoetin beta in IPSS low-risk and intermediate-1 myelodysplastic syndrome patients resistant to erythropoieti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• epoetin beta (epoetin beta)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED